These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27310478)

  • 21. Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis.
    Ohtsu H; Shimomura A; Miyazaki S; Yonemoto N; Ueda S; Shimizu C; Sase K
    Open Heart; 2022 Aug; 9(2):. PubMed ID: 35995458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    Abdel-Qadir H; Thavendiranathan P; Austin PC; Lee DS; Amir E; Tu JV; Fung K; Anderson GM
    J Natl Cancer Inst; 2019 Aug; 111(8):854-862. PubMed ID: 30715404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
    Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
    Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
    Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer.
    Allen LA; Yood MU; Wagner EH; Aiello Bowles EJ; Pardee R; Wellman R; Habel L; Nekhlyudov L; Davis RL; Onitilo AA; Magid DJ;
    Med Care; 2014 May; 52(5):e30-8. PubMed ID: 22643199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
    Greenlee H; Iribarren C; Rana JS; Cheng R; Nguyen-Huynh M; Rillamas-Sun E; Shi Z; Laurent CA; Lee VS; Roh JM; Santiago-Torres M; Shen H; Hershman DL; Kushi LH; Neugebauer R; Kwan ML
    J Clin Oncol; 2022 May; 40(15):1647-1658. PubMed ID: 35385342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
    Ezaz G; Long JB; Gross CP; Chen J
    J Am Heart Assoc; 2014 Feb; 3(1):e000472. PubMed ID: 24584736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of uniformity in cardiac assessment during trastuzumab therapy.
    Subar M; Lin W; Chen W; Pittman DG
    Breast J; 2011; 17(4):383-90. PubMed ID: 21615821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Gong IY; Verma S; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Brezden-Masley CB; Gavura S; Peacock S; Chan KK
    Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
    Sukel MP; Breekveldt-Postma NS; Erkens JA; van der Linden PD; Beiderbeck AB; Coebergh JW; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):125-34. PubMed ID: 18058835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
    Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors.
    Vo JB; Ramin C; Veiga LHS; Brandt C; Curtis RE; Bodelon C; Barac A; Roger VL; Feigelson HS; Buist DSM; Bowles EJA; Gierach GL; Berrington de González A
    J Natl Cancer Inst; 2024 Aug; 116(8):1384-1394. PubMed ID: 38718210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
    Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
    Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.